

Amendments to the Claims:

The listing of claims will replace all prior versions, and listing of claims in the application.

Listing of Claims:

- 1-15. (cancelled).
16. (new) A pharmaceutical composition suitable for administration to a human subject comprising a purified abeta antibody wherein the antibody is expressed in a cell line that endogenously produces an abeta peptide and wherein the antibody purified from such cell line has an undetectable concentration of or has acceptably low levels of endogenously produced abeta peptide.
17. (new) A process for preparing an abeta antibody comprising the steps of:
- a. expressing the antibody in cells that endogenously express abeta peptide;
 - b. adding a beta or gamma secretase inhibitor to media used to grow the cells;
and
 - c. purifying the antibody from the growth media wherein the purified antibody has an undetectable concentration or has acceptably low levels of endogenously produced abeta peptide.
18. (new) The process of Claim 17 wherein a gamma secretase inhibitor is added to the media.
19. (new) The process of Claim 18 wherein the cells are mammalian cells.
20. (new) The process of Claim 18 wherein the cells are hamster, human, or mouse cells.
21. (new) The process of Claim 18 wherein the cells are selected from the group consisting of CHO, HEK 293, PER.C6, and NS0 cells.
22. (new) A process for preparing an abeta antibody comprising the steps of:

- a. expressing the antibody in cells that endogenously produce abeta peptide;
- b. increasing alpha-secretase activity in such cells;
- c. purifying the antibody from the media used to grow the cells wherein the purified antibody has an undetectable concentration or has acceptably low levels of endogenously produced abeta peptide.